001     295842
005     20241214120757.0
037 _ _ |a DKFZ-2024-02659
100 1 _ |a Hanne, Malte
|0 P:(DE-He78)9bc7437d3c410002e64b4b6133d0102d
|b 0
|u dkfz
245 _ _ |a Synthesis of Targeted Degraders and Inhibitors for Branched-Chain Amino Acid Aminotransferase 1
260 _ _ |c 2024
336 7 _ |a Output Types/Supervised Student Publication
|2 DataCite
336 7 _ |a Thesis
|0 2
|2 EndNote
336 7 _ |a MASTERSTHESIS
|2 BibTeX
336 7 _ |a masterThesis
|2 DRIVER
336 7 _ |a Master Thesis
|b master
|m master
|0 PUB:(DE-HGF)19
|s 1734096629_9063
|2 PUB:(DE-HGF)
336 7 _ |a SUPERVISED_STUDENT_PUBLICATION
|2 ORCID
502 _ _ |a Masterarbeit, University of Heidelberg, 2024
|c University of Heidelberg
|b Masterarbeit
|g Faculty of Chemistry and Earth Sciences
520 _ _ |a Branched-chain amino acid transferase 1 (BCAT1), the cytosolic isozyme of BCAT, is an enzyme that catalyzes the transamination reaction of branched-chain amino acids, such as leucine or valine, towards α-keto acids to fuel the citric acid cycle, while also being suspected of showing a moonlighting function in mitosis. In the literature, a high abundance of BCAT1 in a number of cancer types has been reported, with BCAT1 knock-out cells showing reduced cell proliferation. These findings make it a promising target in medicinal chemistry, with a number of recent approaches targeting the enzyme.In this thesis, a number of different targeted degraders (PROTACs) and inhibitors for BCAT1 is reported, with different structural modifications being screened to improve activity and cell permeability. The obtained inhibitors are tested for activity against BCAT1 in an enzyme assay, and for cell permeability using a Caco-2 assay.
536 _ _ |a 311 - Zellbiologie und Tumorbiologie (POF4-311)
|0 G:(DE-HGF)POF4-311
|c POF4-311
|f POF IV
|x 0
909 C O |o oai:inrepo02.dkfz.de:295842
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)9bc7437d3c410002e64b4b6133d0102d
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-311
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Zellbiologie und Tumorbiologie
|x 0
914 1 _ |y 2024
920 1 _ |0 I:(DE-He78)A390-20160331
|k A390
|l AG Wirkstoffforschung
|x 0
980 _ _ |a master
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A390-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21